Clinical trial
Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients
NCT00293202 · Kaysen, George A., M.D., Ph.D., Other · Terminated
Key facts
| NCT number | NCT00293202 |
|---|---|
| Title | Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients |
| Official title | The Effect of Etanercept in Suppression of the Systemic Inflammatory Response in Hemodialysis Patients |
| Lead sponsor | Kaysen, George A., M.D., Ph.D., Other |
| Collaborators | Amgen Industry Dialysis Clinic, Inc. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | End Stage Renal Disease |
| Intervention type | Drug |
| Interventions | Etanercept, Placebo |
| Enrollment | 10 |
| Start date | Jan 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Jun 1, 2010 |
| First posted | Feb 17, 2006 |
| Last update posted | Jul 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: